Research & Development
Dizlin’s research and development resources are currently focusing on products for treatment of Parkinson’s disease.

Parkinson’s Disease
Parkinson’s disease (PD) is the second largest neurodegenerative disease (after Alzheimer’s disease) affecting the Central Nervous System (CNS) and PD is growing rapidly along with an increasing share of elderly in the population.

Pipeline products
Infudopa© is a portfolio of infusion solutions containing levodopa and carbidopa, which allows for injection, short-term continuous intravenous infusion and short-term continuous subcutaneous infusion.

Clinical trials
A clinical trial is currently being performed on Infudopa©, which should be enough comprehensive to serve as a basis for a registration in Europe. The trial is scheduled to be finalized Q1 2020.
“I have an ethical responsibility to contribute to Infudopa© becoming available to patients suffering from Parkinson’s disease”
– Arvid Carlsson – Nobel Prize winner